Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans. 1985

A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen

The concentrations of the (R)- and (S)-enantiomers of fenoprofen (alpha-methyl-3-phenoxy-benzeneacetic acid) were measured in plasma and urine of volunteers after oral administration of the (R,S)-racemate. In addition, urinary concentrations of the (R)- and (S)-4'-hydroxy metabolite of fenoprofen, the major metabolite, were measured. The (R)-enantiomer of fenoprofen was stereoselectively inverted to (S)-fenoprofen, which was the major isomeric form found in plasma and urine. A potency comparison of the enantiomers in vitro showed the (S)-isomer to be 35 times more active than the (R)-isomer in inhibiting the fatty acid cyclo-oxygenase pathway from human platelets. In vivo, the similar pharmacological potency of the two enantiomers previously observed in experimental animals may have been due to the rapid inversion of the (R)- to (S)-isomer.

UI MeSH Term Description Entries
D008297 Male Males
D010666 Phenylpropionates Derivatives of 3-phenylpropionic acid, including its salts and esters.
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D005279 Fenoprofen A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent. Fenoprofen Calcium,Fenoprofen Dihydrate, Calcium Salt,Fenoprofen, Anhydrous, Calcium Salt,Nalfon,Nalgesic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016861 Cyclooxygenase Inhibitors Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. Cyclo-Oxygenase Inhibitor,Cyclooxygenase Inhibitor,Prostaglandin Endoperoxide Synthase Inhibitor,Prostaglandin Endoperoxide Synthase Inhibitors,Prostaglandin Synthase Inhibitor,Prostaglandin Synthase Inhibitors,Prostaglandin Synthesis Antagonist,Prostaglandin Synthesis Antagonists,Cyclo-Oxygenase Inhibitors,Inhibitors, Cyclo-Oxygenase,Inhibitors, Cyclooxygenase,Inhibitors, Prostaglandin Synthase,Inhibitors, Prostaglandin-Endoperoxide Synthase,Antagonist, Prostaglandin Synthesis,Antagonists, Prostaglandin Synthesis,Cyclo Oxygenase Inhibitor,Cyclo Oxygenase Inhibitors,Inhibitor, Cyclo-Oxygenase,Inhibitor, Cyclooxygenase,Inhibitor, Prostaglandin Synthase,Inhibitors, Cyclo Oxygenase,Inhibitors, Prostaglandin Endoperoxide Synthase,Synthase Inhibitor, Prostaglandin,Synthesis Antagonist, Prostaglandin

Related Publications

A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
January 1979, Drug metabolism and disposition: the biological fate of chemicals,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
April 1993, Clinical pharmacology and therapeutics,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
July 2001, Chirality,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
October 2000, Journal of veterinary pharmacology and therapeutics,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
August 1991, The Journal of pharmacology and experimental therapeutics,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
June 2002, Veterinary research communications,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
December 1991, The Journal of pharmacology and experimental therapeutics,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
November 2011, Veterinary journal (London, England : 1997),
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
November 1991, Journal of pharmaceutical sciences,
A Rubin, and M P Knadler, and P P Ho, and L D Bechtol, and R L Wolen
February 1998, Journal of clinical pharmacology,
Copied contents to your clipboard!